drugset / Trial / NCT06457919
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/2
Recruiting
50 enrolled
Memorial Sloan Kettering Cancer Center
TransThera Sciences · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2024-06-04
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Prednisone | Other / unclassified | 5 mg | Oral |
| Subject | Tinengotinib | Small molecule | 10 mg | Oral |